Amy Rudolph, PhD, Appointed to Thryv Therapeutics' Board to Enhance Heart Failure Portfolio Thryv Therapeutics has appointed Dr. Amy Rudolph to its Board of Directors, bringing over 25 years of pharmaceutical expertise to support advancements in heart failure treatments.

Amy Rudolph, PhD, Appointed to Thryv Therapeutics' Board to Enhance Heart Failure Portfolio #Canada #Montreal #Thryv_Therapeutics #SGK1_inhibitors #Amy_Rudolph